Major Depressive Disorder is among the most acute, prevalent pathologies worldwide, and can overshadow a patient's life in various ways. Traditional depression treatments, such as antidepressants, often intensify the despair by failing to provide an adequate solution for many patients, due to disadvantages such as efficacy issues and severe side effects*, while ECT carries a risk for memory loss, and entails anesthesia and/or hospitalization*.
Brainsway – A New Dawn in TMS for Depression
Brainsway* has begun a new era in depression treatment, with a safe, effective* drug-free solution which can restore wellbeing for patients. Brainsway's Deep TMS for depression is a non-invasive treatment which can stimulate the brain region responsible for depression and generate significant improvement.
A generally well-tolerated* outpatient treatment, Brainsway Deep TMS therapy does not require hospitalization or anesthesia, and does not entail risks for memory loss, systemic side effects* or an indefinite drug regime.
Short Sessions that Integrate into the Patient's Routine
Brainsway's Deep TMS for depression is effective for a a wide variety of cases, ranging from mild to persistent treatment-resistant depression*. It offers effective results in almost half the time of other treatments (just 20 minutes per session compared to 37 with traditional TMS), requiring daily sessions over 4-6 weeks.
TMS Therapy Sessions that Fit into Patients' Daily Routine
In each TMS therapy session, the patient is comfortably seated in a chair, and a cushioned helmet is gently placed over the head. The helmet generates brief magnetic fields, at a similar amplitude to that used in magnetic resonance imaging (MRI) systems. After each session, patients can return home independently, and immediately resume their daily routine.
The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K122288.